All In Biotech

Free tool

FAERS Monitor: Zioptan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202514 or its brand name (Zioptan, Tafluprost). Reports on generic versions are filed under their own applications.

Reports

2,936

Serious

1,030

35% of reports

Hospitalization

291

Death reported

330

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ocular hyperaemia467
  • eye irritation432
  • eye pain299
  • eye pruritus232
  • drug ineffective215
  • death198
  • vision blurred178
  • headache169
  • eye swelling124
  • dry eye113
  • intraocular pressure increased98
  • photophobia87
  • lacrimation increased76
  • dizziness74
  • dyspnoea71

Reports by year received

View as table
YearReports
20101
201117
2012111
2013174
201499
201595
2016134
2017211
2018160
2019353
2020484
2021265
2022249
2023207
2024154
2025136
202686

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,223 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ocular hyperaemiaSignal46771.265.532,000
intraocular pressure increasedSignal9855.345.55,139
eye irritationSignal43254.249.622,383
eye pruritusSignal23249.844.010,987
eye painSignal29938.234.310,755
photophobiaSignal8733.327.02,682
eye swellingSignal12424.020.22,700
lacrimation increasedSignal7618.114.51,207
dry eyeSignal11316.313.61,602
vision blurredSignal1789.38.11,317
headache1691.91.777
death1981.61.452
drug ineffective2151.21.05
dizziness741.10.80
dyspnoea710.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.